Image may be NSFW.
Clik here to view.
Medtronic (NYSE:MDT) touted data today showing that intrathecal baclofen therapy delivered via the company’s SychroMed II infusion pump performed better than the conventional treatment for patients with severe post-stroke spasticity.
The medtech titan’s SynchroMed II pump is the only device approved in the U.S. for ITB therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity appeared first on MassDevice.
